Array Biopharma Inc. shares (NASDAQ:ARRY) climbed 14.3 percent to $4.47 Thursday as Novartis AG returned full rights to the phase III MEK inhibitor, binimetinib, pledging up to $85 million plus significant follow-on support for Array’s plans to seek approval for using the drug to treat NRAS-mutant melanoma during the first half of 2016.